According to Sorrento Therapeutics 's latest financial reports the company's total assets are $0.45 B. A companyโs total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Year | Total assets | Change |
---|---|---|
2022-12-31 | $0.47 B | -31.95% |
2021-12-31 | $0.69 B | 29.67% |
2020-12-31 | $0.53 B | -3.91% |
2019-12-31 | $0.55 B | -10.65% |
2018-12-31 | $0.62 B | 44.59% |
2017-12-31 | $0.43 B | 7.48% |
2016-12-31 | $0.40 B | 16.9% |
2015-12-31 | $0.34 B | 142.7% |
2014-12-31 | $0.14 B | 52.88% |
2013-12-31 | $92.58 M | 1265.19% |
2012-12-31 | $6.78 M | 48.43% |
2011-12-31 | $4.56 M | -19.67% |
2010-12-31 | $5.68 M | 60.05% |
2009-12-31 | $3.55 M | |
2008-12-31 | $N/A | -100% |
2007-12-31 | $0.02 M | |
2006-12-31 | $N/A | |
2005-12-31 | $N/A | |
2004-12-31 | $N/A | |
2003-12-31 | $N/A |
Company | Total assets | differencediff. | Country |
---|---|---|---|
Karyopharm Therapeutics
KPTI | $0.24 B | -47.35% | ๐บ๐ธ USA |
Exelixis EXEL | $2.80 B | 513.93% | ๐บ๐ธ USA |
Dicerna Pharmaceuticals DRNA | N/A | N/A | ๐บ๐ธ USA |